Table 3.
Prior treatment exposure
| Treatment | Patients receiving RP2D n = 59 | All treated patients n = 84 |
|---|---|---|
| Median prior lines of therapy (range) | 3 (2‐10) | 3 (2‐10) |
| Prior stem cell transplant, n (%) | 59 (100) | 84 (100) |
| Prior lenalidomide, n (%) | 58 (98) | 82 (98) |
| Refractory to lenalidomide, n (%) | 40 (68) | 58 (69) |
| Prior bortezomib, n (%) | 59 (100) | 84 (100) |
| Refractory to bortezomib, n (%) | 41 (69) | 59 (70) |
| Refractory to lenalidomide and bortezomib, n (%) | 28 (47) | 42 (50) |
| Last treatment was a combination of a PI and an IMID, n (%) | 7 (12) | 15 (18) |
| Disease status to last treatment, n (%)a | ||
| Relapsed | 5 (8) | 9 (11) |
| Refractory | 53 (90) | 74 (88) |
Abbreviations: IMID, immunomodulatory drug; PI, proteasome inhibitor; RP2D, recommended phase 2 dose.
a
One patient had unknown disease status to their last treatment.